Influenza Virus Vector Vaccine Market is Booming Worldwide – Analysts Expect Robust Growth During 2020 – QYResearch

Industry: Market Research

QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group

Los Angeles, CA (PRUnderground) April 21st, 2020

This report focuses on demand and consumption of Influenza Virus Vector Vaccine in key countries, like U.S., Spain, Italy, France, UK, Germany, China and Japan, etc.

Key Findings 1: The Technology Principle of Influenza Virus Vector Vaccine

The vector technology of attenuated influenza virus has the same basic principle as that of adenovirus. It inserts the gene sequence of the target antigen into the genome of influenza virus, infects the human body with attenuated influenza virus, and expresses the relevant antigen through human cells. Attenuated influenza virus vector is a relatively new virus vector vaccine preparation technology which is not widely used in current vaccine development. It is considered an attractive vaccine carrier because of its ability to induce long-term mucosal, humoral and cellular immune responses.

Get PDF report template @

Figure 1.   Distribution of Gene-based Advanced Therapy Medicinal Products in Development Based on Viral or Plasmid Platform Used to Express Gene of Interest



Key Findings 2: The Research and Development Progress of Influenza Virus Vector Vaccine

The university of Hong Kong attenuated influenza virus vector project is expected to conclude the pre-clinical study and apply for clinical trial by the end of April; The Russian company BiOCAD has also carried out the research on the new coronavirus vector vaccine, which is currently in the pre-clinical research stage.

Key Influenza Virus Vector Vaccine Developers and Suppliers Covered in This report

Table 1.   Global Representative Influenza Virus Vector Vaccine Developers/Suppliers and R&D Stage

Company Headquarter/Country R&D Stage
GREFFEX the United States Clinical Stage I
CanSino   Biologics China Clinical II
Academy of Military Medical   Sciences India Preclinical
XMU China zoopery
HKU China zoopery
Hualan   Biological Engineering China zoopery
BravoBio China Being developed

Source: Above companies and QYResearch, 2020

  • CanSino Biologics
  • Academy of Military Medical Sciences
  • XMU
  • HKU
  • Hualan Biological Engineering
  • BravoBio
  • Type Seven
  • Type Eight

Key Findings 3: Evaluation of Influenza Virus Vector Technology Route

The current influenza virus culture technology is relatively mature. China issues about 30 million doses of influenza vaccine in batches every year, and the global annual production capacity of influenza vaccine is over 1.5 billion doses. The new influenza virus vector vaccine is expected to achieve mass production based on the existing influenza virus culture platform.

In the development of influenza virus vector vaccine to be administered by nasal spray, compared with the traditional injection delivery method is more convenient, which is conducive to the rapid expansion of the vaccination scope.

If successful, the novel coronavirus vector vaccine can prevent both novel coronavirus infection and influenza virus infection, with multiple advantages. Disadvantages: the exploration of adenovirus, vesicular stomatitis virus and other vectors has been relatively mature, compared with the research of influenza virus vectors is still in the early stage, its safety and immunogenicity are still uncertain.

Get Customized Report in your Inbox within 24 hours @

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

About QY Research

QY Research is a leading global market research and consulting company. Established in 2007 in Beijing, China, QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and custom research to help our clients in providing non-linear revenue models and make them successful. We are globally recognized for our expansive portfolio of services.

Print Friendly, PDF & Email

Become a Fan

Press Contact

Rahul Singh
+1 626 428 8800
Contact Us